Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep;9(9):2132-4.
doi: 10.3748/wjg.v9.i9.2132.

Ultrasonography guided percutaneous radiofrequency ablation for hepatic cavernous hemangioma

Yan Cui  1 , Li-Yan Zhou, Man-Ku Dong, Ping Wang, Min Ji, Xiao-Ou Li, Chang-Wei Chen, Zi-Pei Liu, Yong-Jie Xu, Hong-Wen Zhang
Affiliations

Ultrasonography guided percutaneous radiofrequency ablation for hepatic cavernous hemangioma

Yan Cui et al. World J Gastroenterol. 2003 Sep.

Abstract

Aim: Hepatic cavernous hemangioma (HCH) is the most common benign tumor of the liver and its management is still controversial. Recent success in situ radiofrequency ablation of hepatic malignancies has led us to consider using this technique in patients with HCH. This study was to assess the efficacy, safety, and complications of percutaneous radiofrequency ablation (PRFA) under ultrasonography guidance in patients with HCH.

Methods: Twelve patients (four men and eight women, age ranged 33-56 years, mean age was 41.7 years) with 15 hepatic cavernous hemangiomas (2.5 cm to 9.5 cm) were treated using the RF-2000 generator and 10-needle LeVeen electrode percutaneously guided by B-ultrasound. Lesions larger than 3 cm were treated by multiple overlapping ablations that encompass the entire lesion as well as a rim of normal liver tissue (approximately 0.5 cm).

Results: All the patients who received PRFA therapy had no severe pain, bleeding or bile leakage during and after the procedures. Nine to 34 months' follow-up (mean, 21 months) by ultrasound and/or spiral CT scan demonstrated that the ablated lesions in this group were shrunk remarkably, and the shrunken range was 38-79 % (mean, 67 % per 21 months). The contrast enhancement was disappeared within the tumor or at its periphery in all cases on spiral CT scans obtained 3 to 6 months after treatment.

Conclusion: The results of this study suggest that PRFA therapy is a mini-invasive, simple, safe, and effective method for the treatment of selected patients with HCH.

PubMed Disclaimer

References

    1. Kew MC. Tumors of the liver. In: Zakim D, Boyer TD, eds. Hepatology. A textbook of liver disease. Philadelphia: W.B. Saunders Company. 1982:1048–1084.
    1. Smith III RB, Warren WD. The liver. In: Nardi GL, Zuidema GD, eds. Surgery. Essentials of clinical practice. Fourth edition. Boston: Little, Brown and Company. 1982:416–446.
    1. Meyers WC. Neoplasms of the liver. In: Sabiston DC, ed. Text-book of Surgery. The biological basis of modern surgical practice. Thirteenth edition. Philadelphia: W.B.Saunders Company. 1986:1079–1092.
    1. Wu BW, Wu MC, Zhang XH, Chen H, Yao XP, Yang JM, Yang GS. Surgical treatment for cavernous hemangiomas of the liver: 640 cases report. Shijie Huaren Xiaohua Zazhi. 1997;5:644.
    1. Cavernous hemangioma of the liver: clinical analysis of 21 cases. Chin Med J (Engl) 1979;92:61–66. - PubMed